No Data
No Data
BMO Capital Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $50
Tourmaline Bio's TOUR006: Potential Best-in-Class IL-6 Treatment With Strategic Market Positioning
New Analyst Forecast: $TRML Given $50.0 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Wedbush Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $43
Tourmaline Bio Price Target Raised to $43.00/Share From $42.00 by Wedbush